{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:24:25Z","timestamp":1793953465396,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pnpbp.2026.111704","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:11:30Z","timestamp":1776233490000},"page":"111704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparing daytime pharmacokinetic and pharmacodynamic profiles of once-daily lisdexamfetamine versus twice-daily dexamfetamine in adult ADHD"],"prefix":"10.1016","volume":"146","author":[{"given":"R.K.R.W.","family":"Wettstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pirgon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.H.","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1089\/cap.2016.0121","article-title":"Pharmacokinetic and pharmacodynamic properties of lisdexamfetamine in adults with attention-deficit\/hyperactivity disorder","volume":"27","author":"Adler","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111704_bb0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-3956(97)00029-0","article-title":"The use of visual analog scales in mood disorders: a critical review","volume":"31","author":"Ahearn","year":"1997","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00426-019-01245-8","article-title":"Hyperfocus: the forgotten frontier of attention","volume":"85","author":"Ashinoff","year":"2021","journal-title":"Psychol. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111704_bb0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","article-title":"Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study","volume":"29","author":"Biederman","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pnpbp.2026.111704_bib226","doi-asserted-by":"crossref","first-page":"115449","DOI":"10.1016\/j.psychres.2023.115449","article-title":"Prevalence of attention deficit hyperactivity disorder in adults: umbrella review of evidence generated across the globe","volume":"328","author":"Ayano","year":"2023","journal-title":"Psychiatry Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111704_bb0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2007.04.015","article-title":"Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study","volume":"62","author":"Biederman","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.brainresrev.2008.07.001","article-title":"Mental fatigue: costs and benefits","volume":"59","author":"Boksem","year":"2008","journal-title":"Brain Res. Rev."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111704_bb0035","first-page":"211","article-title":"The use of analogue scales in rating subjective feelings","volume":"47","author":"Bond","year":"1974","journal-title":"Psychol. Psychother. Theory Res. Pract."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111704_bb0040","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/17512433.2022.2112950","article-title":"What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion","volume":"15","author":"Carton","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13318-016-0346-1","article-title":"Methylphenidate for treating ADHD: a naturalistic clinical study of methylphenidate blood concentrations in children and adults with optimized dosage","volume":"42","author":"Cherm\u00e1","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2026.111704_bb0050","series-title":"Guideline on the Investigation of Bioequivalence. Revision 1 (CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr)","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2010"},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111704_bb0055","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111704_bib227","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eurpsy.2019.06.011","article-title":"The economic burden of adult attention deficit hyperactivity disorder: a sibling comparison cost analysis","volume":"61","author":"Daley","year":"2019","journal-title":"Eur. Psychiatr.: J. Association of Eur. Psychiatr."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111704_bb0060","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/1087054719897811","article-title":"The impact of sleep deprivation on continuous performance task among young men with ADHD","volume":"25","author":"Dan","year":"2020","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.pnpbp.2026.111704_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00617","article-title":"Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects","volume":"8","author":"Dolder","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111704_bb0070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","article-title":"Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy","volume":"36","author":"Ermer","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.pnpbp.2026.111704_bb0080","first-page":"157","article-title":"Treatment outcomes with licensed and unlicensed stimulant doses for adults with attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis","volume":"82","author":"Farhat","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111704_bb0085","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.euroneuro.2018.08.001","article-title":"Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan","volume":"28","author":"Franke","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111704_bb0090","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/00004583-200310000-00015","article-title":"A pharmacokinetic\/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD","volume":"42","author":"Greenhill","year":"2003","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111704_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ridd.2020.103789","article-title":"Testing the relation between ADHD and hyperfocus experiences","volume":"107","author":"Groen","year":"2020","journal-title":"Res. Dev. Disabil."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2026.111704_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2009.12.029","article-title":"Stress-induced changes in mood and cortisol release predict mood effects of amphetamine","volume":"109","author":"Hamidovic","year":"2010","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111704_bb0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present\u2013a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J. Psychopharmacol. (Oxford, Engl.)"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111704_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0269881109103113","article-title":"Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse","volume":"23","author":"Jasinski","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111704_bb0115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0269881108093841","article-title":"Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers","volume":"23","author":"Jasinski","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111704_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bandc.2022.105880","article-title":"Cognitive control, motivation and fatigue: a cognitive neuroscience perspective","volume":"160","author":"Kok","year":"2022","journal-title":"Brain Cogn."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111704_bb0130","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/0044011-200828120-00002","article-title":"Metabolism, distribution and eliminationof lisdexamfetamine dimesylate","volume":"28","author":"Krishnan","year":"2008","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cogbrainres.2005.01.018","article-title":"Impaired cognitive control and reduced cingulate activity during mental fatigue","volume":"24","author":"Lorist","year":"2005","journal-title":"Cogn. Brain Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12955-018-0876-0","article-title":"Validation of the adapted leeds sleep evaluation questionnaire in Ethiopian university students","volume":"16","author":"Manzar","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.pnpbp.2026.111704_bb0145","series-title":"Dexamfetamine Sulfate 5 mg Tablets - Summary of Product Characteristics (SmPC)","author":"Medicines and Healthcare products Regulatory Agency (MHRA)","year":"2025"},{"key":"10.1016\/j.pnpbp.2026.111704_bb0150","series-title":"Elvanse 30mg Hard Capsules - Summary of Product Characteristics (SmPC)","author":"Medicines and Healthcare products Regulatory Agency (MHRA)","year":"2025"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/S0004-282X2012000200004","article-title":"Performance patterns in Conner\u2019s CPT among children with attention deficit hyperactivity disorder and dyslexia","volume":"70","author":"Miranda","year":"2012","journal-title":"Arq. Neuropsiquiatr."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-012-2954-z","article-title":"The drug effects questionnaire: psychometric support across three drug types","volume":"227","author":"Morean","year":"2013","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111704_bb0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/jcp.0b013e3181515205","article-title":"Do formulation differences alter abuse liability of methylphenidate?","volume":"27","author":"Parasrampuria","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The leeds sleep evaluation questionnaire in psychopharmacological investigations\u2014a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111704_bb0175","series-title":"Clinical Documentation for QbTest and QbCheck","author":"QbTech","year":"2025"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111704_bb0180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1177\/1087054712472981","article-title":"Behavioral assessment of core ADHD symptoms using the QbTest","volume":"19","author":"Reh","year":"2015","journal-title":"J. Atten. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111704_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12402-018-0277-6","article-title":"The positive aspects of attention deficit hyperactivity disorder: a qualitative investigation of successful adults with ADHD","volume":"11","author":"Sedgwick","year":"2019","journal-title":"ADHD Atten. Defic. Hyperact. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111704_bb0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jcph.801","article-title":"Measurement of drug liking in abuse potential studies: a comparison of unipolar and bipolar visual analog scales","volume":"57","author":"Setnik","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111704_bb0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/0269881116631650","article-title":"Individual differences in timing of peak positive subjective responses to d-amphetamine: relationship to pharmacokinetics and physiology","volume":"30","author":"Smith","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2026.111704_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-4328(01)00433-8","article-title":"Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD","volume":"130","author":"Swanson","year":"2002","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0205","first-page":"55","article-title":"Objective and subjective measures of the pharmacodynamic effects of adderall in the treatment of children with ADHD in a controlled laboratory classroom setting","volume":"34","author":"Swanson","year":"1998","journal-title":"Psychopharmacol. Bull."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111704_bib228","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/cap.2019.0043","article-title":"New formulations of stimulants: an update for clinicians","volume":"29","author":"Steingard","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111704_bb0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0009-9236(99)70038-X","article-title":"Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children","volume":"66","author":"Swanson","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111704_bb0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hup.534","article-title":"Cross-cultural validation of the leeds sleep evaluation questionnaire (LSEQ) in insomnia patients","volume":"18","author":"Tarrasch","year":"2003","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.pnpbp.2026.111704_bb0220","series-title":"Technical Manual QbTest","author":"Ulberstad","year":"2012"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111704_bb0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-9081-6-34","article-title":"Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design","volume":"6","author":"Wigal","year":"2010","journal-title":"Behav. Brain Funct."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:30:22Z","timestamp":1793950222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626001016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"alternative-id":["S0278584626001016"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111704","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing daytime pharmacokinetic and pharmacodynamic profiles of once-daily lisdexamfetamine versus twice-daily dexamfetamine in adult ADHD","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111704"}}